ID   Lipo-DUE1
AC   CVCL_4U68
DR   Wikidata; Q54902549
RX   PubMed=26373732;
CC   Doubling time: ~2.8 days (PubMed=26373732).
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=26373732
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D10S1248: 13,15
ST   D12S391: 20,22
ST   D13S317: 8
ST   D16S539: 10,12
ST   D18S51: 12,18
ST   D19S433: 15
ST   D1S1656: 17.3,18.3
ST   D21S11: 29,34.2
ST   D22S1045: 15
ST   D2S1338: 20,24
ST   D2S441: 10,11
ST   D3S1358: 14,16
ST   D5S818: 10
ST   D7S820: 8,11
ST   D8S1179: 10,13
ST   FGA: 22
ST   SE33: 26.2,28.2
ST   TH01: 9.3
ST   TPOX: 11
ST   vWA: 17
DI   NCIt; C3704; Dedifferentiated liposarcoma
DI   ORDO; Orphanet_99970; Dedifferentiated liposarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 10-04-25; Version: 9
//
RX   PubMed=26373732; DOI=10.1007/s13277-015-4050-6;
RA   Mersch S., Riemer J.C., Schlunder P.M., Ghadimi M.P., Ashmawy H.,
RA   Mohlendick B., Topp S.A., Arent T., Kropil P., Stoecklein N.H.,
RA   Gabbert H.E., Knoefel W.T., Krieg A.;
RT   "Peritoneal sarcomatosis: site of origin for the establishment of an
RT   in vitro and in vivo cell line model to study therapeutic resistance
RT   in dedifferentiated liposarcoma.";
RL   Tumor Biol. 37:2341-2351(2016).
//